In Review: Senate President Troy Jackson (D) introduced two bills related to pharmacy benefits, LD 2096 and LD 2114. LD 2096 would require coverage of non-opioid, non-narcotic drugs on a plan’s formulary. Additionally, a plan is prohibited from establishing utilization management requirements for non-opioid, non-narcotic drugs that are more restrictive than utilization management requirements for opioid or narcotic drugs. LD 2114 would require coverage of all generic and biosimilar products on a plan’s formulary with a wholesale acquisition cost less than the branded product. The bill would also prohibit utilization management requirements for generic drugs or biosimilars. Our concern is with generic exclusivity, where a branded product with a rebate has a lower net cost to the plan than the generic. This would result in increased costs to the healthcare system. PCMA will oppose these bills and will plan on meeting with the bill sponsor to walk through our concerns with the bill.

If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.